Randomized, Double-Blind Study of SR142801 (Osanetant). A Novel Neurokinin-3 (NK3) Receptor Antagonist in Panic Disorder with Pre- and Posttreatment Cholecystokinin Tetrapeptide (CCK-4) Challenges

G. Kronenberg; P. Berger; R. F. Tauber; B. Bandelow; V. Henkel; I. Heuser

doi:10.1055/s-2005-837768

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2005; 38(1): 24-29
DOI: 10.1055/s-2005-837768

Original Paper

Randomized, Double-Blind Study of SR142801 (Osanetant). A Novel Neurokinin-3 (NK3) Receptor Antagonist in Panic Disorder with Pre- and Posttreatment Cholecystokinin Tetrapeptide (CCK-4) Challenges

G. Kronenberg¹ , P. Berger² , R. F. Tauber³ , B. Bandelow⁴ , V. Henkel⁵ , I. Heuser¹

¹Psychiatric Department, Charité-CBF, Free University of Berlin, Germany
²Psychiatric Department, University of Vienna, Austria
³Psychiatric Department, University of Jena, Germany
⁴Psychiatric Department, University of Goettingen, Germany
⁵Sanofi-Synthelabo Research, Germany

Abstract

Objective: The present study was designed to examine the efficacy and tolerability of the non-peptide neurokinin-3 (NK3) receptor antagonist SR142801 in outpatients suffering from panic disorder. Methods: In a pilot study, 52 patients who were responders to a cholecystokinin tetrapeptide (CCK-4) challenge were randomized to four weeks of treatment with SR142801 (n = 36) or placebo (n = 16). Panic symptoms were assessed on weekly visits and a second CCK-4 challenge was performed at the end of the double-blind placebo controlled treatment period. Tolerability of SR142801 was generally good. Results: The proportion of patients who had at least one adverse event (AE) in the SR142801 group and the placebo group was similar (58.3 and 50 %, respectively). Independent of treatment group, patients’ overall panic symptomatology was substantially improved at the end of the treatment. Conclusion: With regard to efficacy of outcome, the compound was not significantly different from placebo. However, post-CCK-4 plasma prolactin concentrations showed a significant difference between placebo and SR142801.

Volltext

Referenzen

References

1 American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th edition American Psychiatric Association 1994
2 Association for Methodology and Documentation in Psychiatry (AMDP) and Collegium Internationale Psychiatriae Scalarum (CIPS) (1990). Rating Scales for psychiatry, Beltz Test Weinheim, Germany;
3 Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II The Panic and Agoraphobia Scale. Int Clin Psychopharmacol. 1995; 10 73-81
4 Bert L, Rodier D, Bougault I, Allouard N, Le-Fur G, Soubrie P, Steinberg R. Permissive role of neurokinin NK(3) receptors in NK(1) receptor-mediated activation of the locus coeruleus revealed by SR 142 801. Synapse. 2002; 43 62-69
5 Bradwejn J, Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry. 1994; 151 261-263
6 Bremner J D, Krystal J H, Southwick S M, Charney D S. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse. 1996; 23 39-51
7 Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry. 1998; 155 603-609
8 Butler P D, Weiss J M, Stout J C, Nemeroff C B. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci. 1990; 10 176-183
9 Charney D S, Heninger G R, Redmond D E. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 1983; 33 19-29
10 Coplan J D, Liebowitz M R, Gorman J M, Fyer A J, Dillon D J, Campeas R B, Davies S O, Martinez J, Klein D F. Noradrenergic function in panic disorder - effects of intravenous clonidine pretreatment on lactate induced panic. Biol Psychiatry. 1992; 31 135-146
11 de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry. 1989; 46 511-517
12 Dillon D J, Gorman J M, Liebowitz M R. The measurement of lactate-induced panic and anxiety. Psychiatry Res. 1987; 20 97-105
13 Flores C M, Hulihan-Giblin B A, Hornby P J, Lumpkin M D, Kellar K J. Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology. 1992; 55 519-528
14 Gorman J M, Kent J M, Sullivan G M, Coplan J D. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000; 157 493-505
15 Gorman J M, Martinez J M, Goetz R, Huppert J D, Ray S, Barlow D H, Shear M K, Woods S W. The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depress Anxiety. 2003; 17 88-93
16 Guaiana G, Barbui C. A systemic review of the European Agency for the evaluation of medicinal products (EMEA) recommendations on the conduct of clinical trials in psychiatry. Epidemiol Psichiatr Soc. 2002; 11 28-34
17 Hauri P J, Friedman M, Ravaris C L. Sleep in patients with spontaneous panic attacks. Sleep. 1989; 12 323-337
18 Jung M, Michaud J C, Steinberg R, Barnouin M C, Hayar A, Mons G, Souilhac J, Emonds-Alt X, Soubrie P, Le Fur G. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Neuroscience. 1996; 74 403-414
19 Keck M E, Welt T, Muller M B, Landgraf R, Holsboer F. The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry. 2003; 36 27-31
20 Kellner M, Yassouridis A, Jahn H, Wiedemann K. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology (Berl). 1997; 133 55-61
21 Koszycki D, Zacharko R M, Le Melledo J M, Bradwejn J. The effects of CCK-4 in normal individuals: comparison of panickers and nonpanickers. Eur Psychopharmacol. 1996; 6(Suppl 3) 206
22 Koutcherov Y, Ashwell K W, Paxinos G. The distribution of the neurokinin B receptor in the human and rat hypothalamus. Neuroreport. 2000; 11 3127-3131
23 Kramer M S, Cutler N, Feighner J ., Shrivastava R, Carman J, Sramek J J. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998; 281 1640-1645
24 Kramer M S, Winokur A, Kelsey J, Preskorn S H, Rothschild A J, Snavely D, Ghosh K, Ball W A, Reines S A, Munjack D, Apter J T, Cunningham L, Kling M, Bari M, Getson A, Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004; 29 385-392
25 Kronenberg G, Schredl M, Fiedler K, Heuser I. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep. Depress Anxiety. 2001; 14 141-144
26 Krystal J H, Webb E, Cooney N L, Kranzler H R, Southwick S W, Heninger G R, Charney D S. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Am J Psychiatry. 1996; 153 83-92
27 Le Melledo J M, Bradwejn J, Koszycki D, Bichet D G, Bellavance F. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry. 1998; 44 364-366
28 Osterbaan D B, van Balkom A J, Spinhoven P, van Dyck R. The placebo response in social phobia. J Psychopharmacol. 2001; 15 199-203
29 Otte C, Kellner M, Arlt J, Jahn H, Holsboer F, Wiedemann K. Prolactin but not ACTH increases during sodium lactate-induced panic attacks. Psychiatry Res. 2002; 109 201-205
30 Oury-Donat F, Carayon P, Thurneyssen O, Pailhon V, Emonds-Alt X, Soubrie P, Le Fur G. Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther.. 1995; 274 148-154
31 Pollack M H, Marzol P C. Panic: course, complications and treatment of panic disorder. J Psychopharmacol. 2000; 14(2 Suppl 1) S 25-30
32 Rasmussen K, Morilak D A, Jacobs B L. Single unit activity of locus coeruleus neurons in the freely moving cat. I. During naturalistic behaviors and in response to simple and complex stimuli. Brain Res.. 1986; 371 324-334
33 Redmond D E, Huang Y H. Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci.. 1979; 25 2149-2162
34 Ribeiro S J, De Lima T C. Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice. Neurosci Lett.. 1998; 258 155-158
35 Rupniak N M, Kramer M S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci.. 1999; 20 485-490
36 Shear M K, Pilkonis P A, Cloitre M, Leon A C. Cognitive behavioral treatment compared with nonprescriptive treatment of panic disorder. Arch Gen Psychiatry. 1994; 51 395-401
37 Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci. 1997; 22 332-340
38 Stratton S C, Beresford I JM, Harvey F J, Turpin M P, Hagan R M, Tyers M B. Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box. Eur J Pharmacol.. 1993; 250 11-12
39 Strohle A, Kellner M, Holsboer F, Wiedemann K. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am J Psychiatry. 2001; 158 1514-1516
40 Tanaka T, Yokoo H, Mizoguchi K, Yoshida M, Tsuda A, Tanaka M. Noradrenaline release in the rat amygdala is increased by stress: studies with intracerebral microdialysis. Brain Res. 1991; 544 174-176
41 Teixeira R M, Santos A R, Ribeiro S J, Calixto J B, Rae G A, De Lima T C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol.. 1996; 311 7-14
42 Tooney P A, Au G G, Chahl L A. Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clin Exp Pharmacol Physiol. 2000; 27 947-949
43 Trivedi M H, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?. Neuropsychopharmacology. 1994; 11 33-43
44 van Megen H J, Westenberg H G, den Boer J A, Slaap B, Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl). 1997; 129 357-364
45 van Megen H J, Westenberg H G, den Boer J A, Slaap B, van Es-Radhakishun F, Pande A C. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (Berl). 1997; 129 243-248
46 Wiedemann K, Herzog L, Kellner M. Atrial natriuretic hormone inhibits corticotropin-releasing hormone-induced prolactin release in man. J Psychiatr Res. 1995; 29 51-58
47 Wiedemann K, Jahn H, Yassouridis A, Kellner M. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry. 2001; 58 371-377
48 Wittchen H, Zaudig M, Frydrich T. Strukturiertes Klinisches Interview für DSM-IV (SKID-I und SKID-II) Achse I: Psychische Störungen/Achse II: Persönlichkeitsstörungen. Hogrefe Verlag 1997
49 Yip J, Chahl L A. Localization of NK1 and NK3 receptors in guinea-pig brain. Regul Pept. 2001; 98 55-62
50 Zwanzger P, Baghai T C, Schuele C, Strohle A, Padberg F, Kathmann N, Schwarz M, Moller H J, Rupprecht R. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001; 25 699-703
51 Zwanzger P, Eser D, Aicher S, Schule C, Baghai T C, Padberg F, Ella R, Moller H J, Rupprecht R. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003; 28 979-984

Isabella Heuser, MD, PhD

Department of Psychiatry

Charité-CBF

Free University Berlin

Eschenallee 3

14050 Berlin

Germany

Telefon: +49 30 8445 8701

Fax: +49 30 8445 8726 ·

eMail: isabella.heuser@charite.de